Form 4 for STRO SUTRO BIOPHARMA, INC.
Accepted 2025-05-05 00:00:00 ET · period of report 2025-05-01 · accession 0001415889-25-011996 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-05-05 | 2025-05-01 | STRO | Borgman Anne Elizabeth | Chief MEDICAL Off | M - OptEx | $0.00 | +69.1K | 106.2K | +186% | $0 |
| D | 2025-05-05 | 2025-05-01 | STRO | Borgman Anne Elizabeth | Chief MEDICAL Off | F - Tax | $1.07 | -24.7K | 97.5K | -20% | -$26.4K |
| DM | 2025-05-05 | 2025-05-01 | STRO | Borgman Anne Elizabeth | Chief MEDICAL Off | M - OptEx | $0.00 | -69.1K | 21.9K | -76% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-01 | M | A | 15,938 | $0.00 | 122,161 | D | — | — | |
| 2 | Common | Common Stock | 2025-05-01 | M | A | 53,125 | $0.00 | 106,223 | D | — | — | |
| 3 | Common | Common Stock | 2025-05-01 | F | D | 24,709 | $1.07 | 97,452 | D | — | — | (F1) Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. |
| 4 | Derivative | Restricted Stock Unit (RSU) | 2025-05-01 | M | D | 15,938 | $0.00 | 17,812 | D | — · — to 2028-03-01 | 15,938 Common Stock | (F2) Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. (F4) The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan and 2021 Equity Inducement Plan, in connection with her separation and transition from her position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025. (F5) The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. |
| 5 | Derivative | Restricted Stock Unit (RSU) | 2025-05-01 | M | D | 53,125 | $0.00 | 21,875 | D | — · — to 2027-02-28 | 53,125 Common Stock | (F2) Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. (F3) The RSU award vests as to 1/4th of the total award annually on the last calendar day of February, beginning on February 29, 2024, subject to continued service through each vesting date. (F4) The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan and 2021 Equity Inducement Plan, in connection with her separation and transition from her position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025. |